The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

What if the food you eat and the way you handle stress could make a real difference for your chronic spontaneous urticaria?

Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...

Hives, also known as urticaria, are raised, itchy welts on your skin that occur due to an allergen. The reaction is ...

The Impact of Targeted Therapy The treatment of chronic urticaria (CU), a condition highlighted by constant itching and hives, is undergoing a notable breakthrough, which majorly pertains to the ...

Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU ... CSU – also known as chronic hives—compared the drug to a placebo.

and painful hives. Credit: Doucefleur via Getty Images. Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...